ArticleCommunications biology2020
Single-cell analysis of a mutant library generated using CRISPR-guided deaminase in human melanoma cells.
Article in Communications biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Harnessing induced pluripotent stem cells and organoids for disease modeling and precision medicine.Stem cell research & therapy · 2026Review
- Endogenous fine-mapping and prioritization of functional regulatory elements in complex genetic loci.Cell genomics · 2025Article
- Identifying TP53RK as a key regulator of colorectal cancer survival and a potential therapeutic target.Scientific reports · 2025Article
- Next generation genetic screens in kinetoplastids.Nucleic acids research · 2025Review
- Deconstructing cancer with precision genome editing.Biochemical Society transactions · 2024Review
- Applications of single‑cell omics and spatial transcriptomics technologies in gastric cancer (Review).Oncology letters · 2024Review
- Recent advances in CRISPR-based functional genomics for the study of disease-associated genetic variants.Experimental & molecular medicine · 2024Review
- Deep mutational scanning of proteins in mammalian cells.Cell reports methods · 2023Review
- CRISPR screening in hematology research: from bulk to single-cell level.Journal of hematology & oncology · 2023Review
- Base editor screens for in situ mutational scanning at scale.Molecular cell · 2023Review
- Base editors: development and applications in biomedicine.Frontiers of medicine · 2023Review
- Article
- Massively Parallel CRISPR-Based Genetic Perturbation Screening at Single-Cell Resolution.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Base editor scanning charts the DNMT3A activity landscape.Nature chemical biology · 2023Article
- The role of single-cell genomics in human genetics.Journal of medical genetics · 2022Review
- CRISPR-based genome editing through the lens of DNA repair.Molecular cell · 2022Review
- Research Progress of Cell Lineage Tracing and Single-Cell Sequencing Technology in Malignant Skin Tumors.Frontiers in surgery · 2022Review
- The use of base editing technology to characterize single nucleotide variants.Computational and structural biotechnology journal · 2022Review
- CRISPR base editing applications for identifying cancer-driving mutations.Biochemical Society transactions · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR-based screening methods using single-cell RNA sequencing (scRNA-seq) technology enable comprehensive profiling of gene perturbations from knock-out mutations. However, evaluating substitution mutations using scRNA-seq is currently limited. We combined CRISPR RNA-guided deaminase and scRNA-seq technology to develop a platform for introducing mutations in multiple genes and assessing the mutation-associated signatures. Using this platform, we generated a library consisting of 420 sgRNAs, performed sgRNA tracking analysis, and assessed the effect size of the response to vemurafenib in the human melanoma cell line, which has been well-studied via knockout-based drop-out screens. However, a substitution mutation library screen has not been applied and transcriptional information for mechanisms of action was not assessed. Our platform permits discrimination of several candidate mutations that function differently from other mutations by integrating sgRNA candidates and gene expression readout. We anticipate that our platform will enable high-throughput analyses of the mechanisms related to a variety of biological events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.